One would be Medicago, of Quebec City. Medicago is a Canadian vaccine company with a very promising vaccine. They received a contribution of $173 million through the SIF program to build out domestic biomanufacturing capacity. There have been other investments such as that through SIF.
The other thing was that we worked very closely with all our existing clients who have received SIF contributions, basically to try to protect the Crown's investment and make sure those companies were able to bridge to the other side. We would look at their repayment schedules. We would look at whether they were experiencing financial distress and how we could maybe adjust their agreements so that they could bridge to the other side of the pandemic.
SIF has pivoted to focus on support for large-scale biomanufacturing and production of materials needed to protect Canadians. We have also pivoted some of the way we administer SIF to try to provide relief to companies so that, frankly, a government program isn't part of the reason they might be facing solvency problems.